IL143367A0 - Peptide based vaccine for influenza - Google Patents

Peptide based vaccine for influenza

Info

Publication number
IL143367A0
IL143367A0 IL14336799A IL14336799A IL143367A0 IL 143367 A0 IL143367 A0 IL 143367A0 IL 14336799 A IL14336799 A IL 14336799A IL 14336799 A IL14336799 A IL 14336799A IL 143367 A0 IL143367 A0 IL 143367A0
Authority
IL
Israel
Prior art keywords
epitopes
influenza
epitope
influenza virus
hla molecules
Prior art date
Application number
IL14336799A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Priority to IL14336799A priority Critical patent/IL143367A0/xx
Publication of IL143367A0 publication Critical patent/IL143367A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL14336799A 1998-11-30 1999-11-28 Peptide based vaccine for influenza IL143367A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL14336799A IL143367A0 (en) 1998-11-30 1999-11-28 Peptide based vaccine for influenza

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12733198A IL127331A0 (en) 1998-11-30 1998-11-30 Peptide-based vaccine for influenza
PCT/IL1999/000640 WO2000032228A2 (en) 1998-11-30 1999-11-28 Peptide-based vaccine for influenza
IL14336799A IL143367A0 (en) 1998-11-30 1999-11-28 Peptide based vaccine for influenza

Publications (1)

Publication Number Publication Date
IL143367A0 true IL143367A0 (en) 2002-04-21

Family

ID=11072200

Family Applications (3)

Application Number Title Priority Date Filing Date
IL12733198A IL127331A0 (en) 1998-11-30 1998-11-30 Peptide-based vaccine for influenza
IL14336799A IL143367A0 (en) 1998-11-30 1999-11-28 Peptide based vaccine for influenza
IL143367A IL143367A (en) 1998-11-30 2001-05-24 Influenza vaccine based on peptides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL12733198A IL127331A0 (en) 1998-11-30 1998-11-30 Peptide-based vaccine for influenza

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL143367A IL143367A (en) 1998-11-30 2001-05-24 Influenza vaccine based on peptides

Country Status (15)

Country Link
US (3) US6740325B1 (xx)
EP (2) EP1135159A2 (xx)
JP (1) JP2002531415A (xx)
KR (1) KR100703571B1 (xx)
AT (1) ATE556719T1 (xx)
AU (1) AU766883B2 (xx)
BR (1) BR9915811A (xx)
CA (1) CA2352454C (xx)
DK (1) DK2204187T3 (xx)
ES (1) ES2389611T3 (xx)
HK (2) HK1040620A1 (xx)
IL (3) IL127331A0 (xx)
NZ (1) NZ511918A (xx)
PT (1) PT2204187E (xx)
WO (1) WO2000032228A2 (xx)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
WO2002026252A1 (fr) * 2000-08-10 2002-04-04 Tsinghua University Vaccin contre le virus de la grippe et son procede de preparation
FI20031536A0 (fi) * 2003-10-20 2003-10-20 Biotie Therapies Oyj Korkean affiniteetin ligandit influenssavirukselle ja menetelmät niiden valmistamiseen
PT2261377E (pt) 2003-11-04 2013-11-29 Univ Tulane Método para prevenir a fusão vírus:células inibindo a função da região de iniciação de fusão em vírus de rna tendo proteínas do invólucro fusogénicas de membrana de classe
GB0716992D0 (en) * 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
EP1846028A4 (en) * 2005-01-05 2010-06-30 Philadelphia Health & Educatio ADMINISTRATION VEHICLES, BIOACTIVE SUBSTANCES AND VIRAL VACCINES
WO2006078657A2 (en) 2005-01-19 2006-07-27 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
FI20060200A0 (fi) * 2005-04-20 2006-02-27 Glykos Finland Oy Menetelmä ihmisen influenssaviruksen sialihahappositoumisspesifisyyden analysoimiseksi
MX2007015105A (es) * 2005-06-01 2008-03-18 Variation Biotechnologies Inc Formulacion de vacuna de influenza a base de peptido.
US7871626B2 (en) * 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
US7468187B2 (en) 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
EP1948227A4 (en) * 2005-10-26 2010-03-31 Protelix Inc COMBINATORY ANTIGEN VACCINE AGAINST FLU
US9533036B2 (en) * 2005-11-07 2017-01-03 Microvax, Llc Methods for generating immune responses to influenza antigens with a secretable CD40L fusion protein
PT1968632E (pt) * 2005-12-06 2012-07-16 Yeda Res & Dev Vacina da gripe melhorada
KR20110110853A (ko) * 2006-01-27 2011-10-07 노파르티스 파르마 아게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
CN106237316A (zh) * 2006-03-07 2016-12-21 法克斯因内特公司 包含血细胞凝集素的组合物、制造其的方法与使用其的方法
US20080208486A1 (en) * 2006-03-23 2008-08-28 Jari Natunen Integrated System, Device and Use Thereof
US8222204B2 (en) 2006-05-03 2012-07-17 The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC Influenza inhibiting compositions and methods
US20110129438A1 (en) * 2006-06-28 2011-06-02 James Robert Swartz Immunogenic protein constructs
FI20060946A0 (fi) * 2006-10-26 2006-10-26 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
EP2139908A4 (en) * 2007-03-12 2011-02-16 Antigen Express Inc REMOVAL OF PROTEIN Li INVOLVED IN Li-RNAi CONSTRUCTIONS IN ANTICANCER IMMUNOTHERAPY
HUE025149T2 (hu) 2007-08-02 2016-01-28 Biondvax Pharmaceuticals Ltd Multimer multiepitóp influenza vakcinák
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
EP3023107A1 (en) 2008-04-21 2016-05-25 Nanobio Corporation Nanoemulsion influenza vaccine
US20090297552A1 (en) * 2008-04-25 2009-12-03 Aderem Alan A Flagellin polypeptide vaccines
WO2009135152A2 (en) 2008-05-02 2009-11-05 University Of Rochester Arrayed detector system for measurement of influenza immune response
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
WO2012097346A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
BR112013018074A2 (pt) 2011-01-13 2020-12-01 Variation Biotechnologies, Inc. métodos para a preparação de vesículas e formulações produzidas a partir dessas
AU2011360572B2 (en) 2011-02-22 2017-03-02 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
JP2014520805A (ja) 2011-07-06 2014-08-25 ナノバイオ コーポレーション ヒト呼吸器合胞体ウイルスワクチン
US10206996B2 (en) 2011-08-22 2019-02-19 Nanobio Corporation Herpes simplex virus nanoemulsion vaccine
WO2013072768A2 (en) 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
RU2698906C2 (ru) 2012-01-27 2019-09-02 Вэриэйшн Биотекнолоджиз, Инк. Способы и композиции для терапевтических агентов
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
CN103961701B (zh) 2013-02-05 2018-09-14 日东电工株式会社 疫苗组合物
EP2762156A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Tape preparation of WT1 peptide cancer vaccine for transdermal administration
KR20140100420A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 또는 점막 투여용 백신 조성물
CA2840978A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for mucosal administration
JP6512567B2 (ja) 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用ｗｔ１ペプチド癌ワクチン組成物
EP2762160A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for mucosal administration
US20140220056A1 (en) 2013-02-05 2014-08-07 Nitto Denko Corporation Vaccine composition for transdermal administration
CN103961697A (zh) 2013-02-05 2014-08-06 日东电工株式会社 粘膜给予用疫苗组合物
CA2841016A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for transdermal administration
IN2014CH00390A (xx) 2013-02-05 2015-07-31 Nitto Denko Corp
RU2531235C2 (ru) 2013-02-15 2014-10-20 Общество с ограниченной ответственностью "Универсальные БиоСистемы" (ООО "УБС") Поливалентная вакцина против гриппа на основе гибридного белка
CN103901202B (zh) * 2014-04-04 2015-08-12 中国人民解放军成都军区疾病预防控制中心 基于共有表位甲型流感病毒抗体通用型竞争性elisa检测方法
WO2016035808A1 (ja) 2014-09-03 2016-03-10 日東電工株式会社 ビスホスホネート剤を含む細胞性免疫用ワクチン医薬組成物
JP6980360B2 (ja) 2014-09-03 2021-12-15 日東電工株式会社 ビスホスホネート剤を含む液性免疫用ワクチン医薬組成物
WO2017022793A1 (ja) 2015-08-06 2017-02-09 日東電工株式会社 免疫誘導促進組成物及びワクチン医薬組成物
US11111277B2 (en) 2016-12-28 2021-09-07 Invvax, Inc. Influenza vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
IL101639A0 (en) 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
AU3036597A (en) * 1996-05-21 1997-12-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for using peptide complexes/major histocompatibility complex to obtain or purify antigen-specific t cells and to stimulate t cells
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza

Also Published As

Publication number Publication date
KR20010089512A (ko) 2001-10-06
HK1040620A1 (zh) 2002-06-21
PT2204187E (pt) 2012-08-10
DK2204187T3 (da) 2012-08-20
US20070122424A1 (en) 2007-05-31
EP2204187B1 (en) 2012-05-09
US6740325B1 (en) 2004-05-25
EP1135159A2 (en) 2001-09-26
WO2000032228A3 (en) 2000-10-05
NZ511918A (en) 2003-08-29
CA2352454C (en) 2013-02-05
IL143367A (en) 2006-09-05
ES2389611T3 (es) 2012-10-29
US7514086B2 (en) 2009-04-07
IL127331A0 (en) 1999-09-22
KR100703571B1 (ko) 2007-04-05
US7192595B2 (en) 2007-03-20
ATE556719T1 (de) 2012-05-15
EP2204187A1 (en) 2010-07-07
HK1145448A1 (en) 2011-04-21
BR9915811A (pt) 2001-08-21
WO2000032228A2 (en) 2000-06-08
AU766883B2 (en) 2003-10-23
CA2352454A1 (en) 2000-06-08
US20050002954A1 (en) 2005-01-06
AU1406600A (en) 2000-06-19
JP2002531415A (ja) 2002-09-24

Similar Documents

Publication Publication Date Title
IL143367A0 (en) Peptide based vaccine for influenza
JP2002531415A5 (xx)
Liu et al. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity
Schild et al. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide.
CA2164818A1 (en) Tandem synthetic hiv-1 peptides
AR008765A1 (es) Un peptido o un derivado, analogo o variante, funcional del mismo, un peptido recombinante o sintetico del mismo, una secuencia nucleotidica y vectorque la contiene, una celula huesped transformada, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un compuesto del
ATE277633T1 (de) Präparate und verfahren zum auslösen von ctl- immunität
RS51602B (sr) April receptor (bcma) i njegova upotreba
EP0259149A3 (en) The use of rotavirus nucleocapsid protein vp6 in vaccine compositions
DK1036058T3 (da) Adamantanderivater
EE200000378A (et) Adamantaani derivaadid
NO880494L (no) Syntetiske nonapeptid- og decapeptidanaloger av lhrh som er anvendelige som lhrh-antagonister.
ES2619332T3 (es) Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
NO990533L (no) GnRH-leukotoksin kimµrer
ES2721172T3 (es) Una nueva clase de moléculas terapéuticas a base de proteínas
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
ES2124922T3 (es) Peptidos derivados de un retrovirus del grupo hiv y su uso.
BR9912176A (pt) Epìtopos de célula auxiliar t artificial como estimuladores imunes para imunógenos de peptìdeo sintéticos incluindo peptìdeos de lhrh imunogênicos
Hackett et al. A synthetic decapeptide of influenza virus hemagglutinin elicits helper T cells with the same fine recognition specificities as occur in response to whole virus.
Wabuke-Bunoti et al. Cytolytic T lymphocyte and antibody responses to synthetic peptides of influenza virus hemagglutinin.
GB2220939B (en) Peptide fragments of hiv and their use in vaccines and diagnosis
ZA943920B (en) Pharmaceutical compositions
Hampl et al. In vitro processing of insulin for recognition by murine T cells results in the generation of A chains with free CysSH.
DE69527708D1 (de) Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus
CA2521038A1 (en) Polypeptide comprising cell adhesion motif, t cell epitope and b cell epitope for inducing antibody production

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed